RecruitingNot ApplicableNCT06466382

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.

Sponsor

Swiss GO Trial Group

Enrollment

60 participants

Start Date

Mar 31, 2025

Study Type

INTERVENTIONAL

Conditions

High-grade Serous Ovarian Carcinoma (HGSOC)Fallopian Tube Neoplasms Ovarian Neoplasm Epithelial Ovarian Endometrioid Carcinoma

Summary

The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether personalizing cancer treatment based on each patient's tumor biology (precision medicine) improves outcomes for newly diagnosed advanced ovarian, peritoneal, or fallopian tube cancer. **You may be eligible if...** - You have been newly diagnosed with advanced ovarian, peritoneal, or fallopian tube cancer (FIGO stage III or IV, including carcinosarcoma) - You are a candidate for surgery after initial chemotherapy (interval debulking) - You are in good overall health (ECOG 0-2) - You do not need immediate treatment and can wait up to 2 weeks after diagnosis **You may NOT be eligible if...** - You require immediate systemic treatment or surgery - You are not willing or able to attend required study visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTreatment recommendation by molecular tumorboard (mTB) based on tumor profiling

The intervention studied is a treatment recommendation by a specialized molecular tumorboard (mTB). This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.

DRUGCarboplatin / Paclitaxel Chemotherapy

2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly